Description:
A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
Recruiting
Phase 2
Drug | Synonyms | Arms |
---|---|---|
ARX788 | antibody drug conjugate (ADC) | HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory |
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens. The ARX788 will be administered every 4 weeks (Q4W) intravenous (IV) infusion.
Name | Type | Description | Interventions |
---|---|---|---|
HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory | Experimental | This global Phase 2 study is designed to assess anticancer activity and safety of ARX788 in HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. The investigational medicinal product (IMP), ARX788, will be administered every 4 weeks (Q4W) by intravenous (IV) infusion. |
|
Inclusion Criteria: - Age ≥ 18 years and older - Life expectancy > 3 months - Eastern Cooperative Oncology Group Performance Status ≤ 1 - Metastatic breast cancer subjects previously treated with T DM1, and/or T-DXd, and/or tucatinib-containing regimens. - Presence of at least one measurable lesion per RECIST v 1.1 - Subjects must have an adequate tumor sample available for confirmation of HER2 status - Subjects with stable brain metastases - Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1 as per the NCI-CTCAE v 5.0, except alopecia. - Adequate organ functions - Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol. - Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at postmenopausal, or who commits to use an acceptable form of birth control; male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control Exclusion Criteria: Any subject who meets any of the following criteria is excluded from the study: - History of allergic reactions to any component of ARX788. - Prior history of interstitial lung disease, pneumonitis, or other clinically significant lung disease within 12 months - History of ocular events, or any current ongoing active ocular infections. - History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment - Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0) - History of unstable central nervous system (CNS) metastases - Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic diseases) - Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments. - Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788. - Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788 - Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0. - Pregnancy or breast feeding. - Known active HCV, HBV, and/or HIV infection.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Measure: | Objective response rate (ORR) |
Time Frame: | 2 Years |
Safety Issue: | |
Description: | The confirmed objective response rate (ORR) of ARX788 based on RECIST 1.1 in HER2-positive breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. The ORR is defined as the number of subjects with a BOR of CR or PR divided by the number of response evaluable subjects. |
Measure: | Duration of response (DOR) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | DOR is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for subjects with a BOR of CR or PR. |
Measure: | Best percent change in the sum of the longest diameters of measurable tumors |
Time Frame: | 2 years |
Safety Issue: | |
Description: | The percent change at the best response data point compared to baseline. |
Measure: | Best overall response (BOR) |
Time Frame: | 2 year |
Safety Issue: | |
Description: | BOR is defined as the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started) |
Measure: | Disease control rate (DCR) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | DCR is defined as the proportion of complete response (CR), partial response (PR), and stable disease (SD) rates. |
Measure: | Progression-free survival (PFS) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy |
Measure: | Overall survival (OS) |
Time Frame: | 2 year |
Safety Issue: | |
Description: | Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive. |
Measure: | The number of subjects experiencing adverse event TEAEs |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Patient safety and adverse events (AEs) will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the treatment. |
Measure: | Maximum serum concentration (Cmax) for ARX788, total antibody, and pAF-AS269 |
Time Frame: | Cycle 1 and cycle 3 |
Safety Issue: | |
Description: | Pharmacokinetic parameter maximum serum concentration (Cmax) for ARX788, total antibody, and pAF-AS269 |
Measure: | Trough concentration (Ctrough) for ARX788, total antibody, and pAF-AS269 |
Time Frame: | Cycle 1 and cycle 3 |
Safety Issue: | |
Description: | Pharmacokinetic parameter trough concentration (Ctrough) for ARX788, total antibody, and pAF-AS269 |
Measure: | Area under the serum concentration-time curve (AUC) for ARX788, total antibody, and pAF-AS269 |
Time Frame: | Cycle 1 and cycle 3 |
Safety Issue: | |
Description: | Pharmacokinetic parameter area under the serum concentration-time curve (AUC) for ARX788, total antibody, and pAF-AS269 |
Measure: | Incidence of anti-drug antibodies (ADAs) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Incidence of anti-drug antibodies (ADAs) following intravenous administration of ARX788 in participants with HER2-positive metastatic breast cancer |
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Ambrx, Inc. |
August 24, 2021